SCHEMBL18369932

SCHEMBL18369932

CN1C(=O)c2ccccc2N(C)c2cc(NC3CCOCC3)ncc21

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPK7 Q13164 11/20 0.77
▸ BRD4 O60885 10/20 0.77
▸ KCNH2 Q12809 1/20 0.44
▸ BRD2 P25440 1/20 0.43
▸ EP300 Q09472 1/20 0.43
▸ BRD3 Q15059 1/20 0.43
▸ BRDT Q58F21 1/20 0.43
▸ CREBBP Q92793 1/20 0.43
▸ MAPK3 P27361 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ DCLK1 O15075 2/20 0.43
▸ LRRK2 Q5S007 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ MAPK14 Q16539 1/20 0.43
▸ CCNE1 P24864 4/20 0.41
▸ CDK2 P24941 4/20 0.41
▸ AOC3 Q16853 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17059926 0.90 MAPK7 (0.82) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18370073 0.90 BRD4 (0.69) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18369899 0.90 BRD4 (0.69) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18369858 0.87 MAPK7 (1.00) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18369908 0.87 MAPK7 (0.80) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL17059803 0.87 MAPK7 (1.00) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL17059837 0.87 MAPK7 (1.00) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18379209 0.86 MAPK7 (0.79) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18379147 0.86 MAPK7 (0.79) MAPK7BRD4KCNH2BRD2EP300
SCHEMBL18379157 0.86 MAPK7 (0.72) MAPK7BRD4KCNH2BRD2EP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed
US-20170008888-A1 HETEROCYCLIC COMPOUNDS ACTIVX BIOSCIENCES, INC. 2017-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008888-A1 HETEROCYCLIC COMPOUNDS BET1, EP300, RBBP5 MAPK7 58/4885BRD4 4/4885KCNH2 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback